01 What is Ipamorelin?
In plain English.
Ipamorelin is a short, lab-made peptide, just five amino acids long, that mimics ghrelin, the body's "hunger" hormone. Its real interest, though, is not appetite. By binding the same pituitary receptor as ghrelin, it triggers a pulse of growth hormone (GH). It was developed by Novo Nordisk in the 1990s and given the code NNC-26-0161 before being licensed on to Helsinn for clinical development.
Its marketing pitch, then and now, is "selectivity": unlike older growth-hormone-releasing peptides (GHRP-2, GHRP-6, hexarelin), ipamorelin is reported to raise GH without meaningfully bumping prolactin, cortisol or ACTH. That cleaner profile is why it became the GHRP of choice in research-peptide and wellness-clinic circles, even though no regulator has approved it for any human use.
02 How it works
The simple version, then the science.
Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a) on pituitary cells, the same receptor used by the body's own ghrelin. That signal tells the pituitary to release a pulse of growth hormone. The GH then drives the liver to make IGF-1, the downstream signal most of GH's muscle, bone and metabolic effects work through.
Go deeper · the proposed mechanism
Mechanistically, ipamorelin is a pentapeptide agonist at GHS-R1a (Aib-His-D-2-Nal-D-Phe-Lys-NH2). Activation triggers Gq-coupled phospholipase C signalling, IP3 release and a calcium-dependent burst of GH from somatotrophs. In Raun et al. 1998, the foundational characterization, the molecule released GH dose-dependently in rats, pigs and isolated pituitary cells, but, unusually for a GHRP, did not raise ACTH or cortisol above baseline at GH-releasing doses. This selectivity profile is the basis of every claim about ipamorelin being a "cleaner" secretagogue. Effects on IGF-1 over time, body composition and recovery are extrapolations from GH-axis pharmacology and have not been demonstrated in adequately powered human trials.
03 What it's used for
Each use graded by how strong the evidence actually is.
- LimitedPost-operative ileus (slow gut after bowel surgery)The one indication ipamorelin reached human trials for. A randomised, placebo-controlled phase 2 study in bowel-resection patients (Beck et al. 2014) reported some signal on gastric motility but missed its primary endpoint. Development was halted.
- PreclinicalGrowth hormone & IGF-1 axis stimulationReliably raises GH in animals and healthy volunteers in short-duration studies. Whether sustained micro-pulses translate to meaningful long-term clinical outcomes in humans is not established.
- Anecdotal
- AnecdotalAnti-ageing & sleep qualityCommon marketing claim based on GH's normal role in sleep and tissue repair. No human clinical data on ipamorelin for these endpoints.
04 What the evidence says
Ipamorelin sits in an awkward middle ground: more clinical data than most "research peptides", but none of it supports the reasons people actually buy it. The trial record is real, Novo Nordisk took the molecule through phase 1 and Helsinn through a randomised placebo-controlled phase 2 in post-op ileus (Beck et al. 2014), but that programme failed its primary endpoint and was abandoned. The animal pharmacology, especially Raun et al. 1998, is solid and reproducible: ipamorelin does raise GH selectively, with minimal effect on prolactin or cortisol. The leap from "raises a GH pulse for an hour in a healthy volunteer" to "builds muscle, burns fat and reverses ageing" is not supported by published human trials. The wellness-medicine literature that endorses it (e.g. Sigalos & Pastuszak 2018, Sinha et al. 2020) is review-and-opinion, not new trial data. In short: a real drug-development story that didn't pan out, repurposed by clinics for indications it was never tested in.
05 Dosing & administration
Reported in the literature, information not advice.
No approved human protocol exists, so no safe or effective dose has been established for any use. The Beck et al. 2014 phase 2 trial used intravenous infusion for hospitalised post-op patients, a context unrelated to how the peptide is used today. Subcutaneous regimens described in wellness-clinic and online communities (typically microgram-per-kilogram doses, sometimes stacked with CJC-1295) are not backed by clinical evidence, and the purity of "research peptide" vials is not regulated. A qualified clinician should be consulted before considering any peptide.
06 Side effects & safety
In short-duration human trials ipamorelin was generally well tolerated, with the most common reports being injection-site reactions, mild headache and transient flushing. Longer-term safety in healthy adults using it for performance or anti-ageing reasons is unknown, there are no multi-month controlled trials in this population. Chronic stimulation of the GH/IGF-1 axis is the main theoretical concern: it could in principle worsen insulin resistance, drive water retention, accelerate diabetic retinopathy, or promote the growth of pre-existing tumours (IGF-1 is mitogenic). People with active cancer, a cancer history, diabetes, or who are pregnant or breastfeeding should not use it. Products sold as "ipamorelin" online are unregulated research chemicals, purity, sterility and dose-per-vial vary, and contamination is a real risk.
07 Where to buy (research use only)
Vetted on quality and transparency, not an endorsement to use.
08 Legal & regulatory status
- UKNot licensed as a medicine. Sold only as a "research chemical", not for human use.
- USNot FDA-approved. Placed on the FDA's Category 2 list for 503A compounding (substances with significant safety risks), effectively blocking compounding-pharmacy supply for human use.
- EU / AUS / CANNo approved human medicine containing ipamorelin. Sale for human consumption is unlawful in most jurisdictions; "research use only" framing is standard.
- Sport (WADA)Prohibited at all times under S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics. Growth hormone secretagogues are explicitly named in the category.
09 Clinical studies & research
Primary sources. Read the science yourself.